MLICM
AKBA icon

Metropolitan Life Insurance Company (MetLife)’s Akebia Therapeutics AKBA Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11,718
Closed -$8.41K – 2368
2022
Q1 		$8.41K Sell
11,718
-30,430
-72% -$65.1K ﹤0.01% 2234
2021
Q4 		$95.3K Sell
42,148
-6,066
-13% -$16.5K ﹤0.01% 2514
2021
Q3 		$139K Buy
48,214
+20,259
+72% +$57.8K ﹤0.01% 2331
2021
Q2 		$106K Sell
27,955
-15,693
-36% -$52.8K ﹤0.01% 2570
2021
Q1 		$148K Buy
43,648
+21,502
+97% +$77.5K ﹤0.01% 2217
2020
Q4 		$62K Buy
22,146
+3,550
+19% +$10.4K ﹤0.01% 2454
2020
Q3 		$46.7K Sell
18,596
-21,577
-54% -$189K ﹤0.01% 2473
2020
Q2 		$546K Buy
40,173
+3,313
+9% +$34.3K 0.01% 1137
2020
Q1 		$279K Sell
36,860
-1,711
-4% -$13.3K 0.01% 1389
2019
Q4 		$244K Buy
38,571
+8,808
+30% +$41.9K ﹤0.01% 1779
2019
Q3 		$117K Sell
29,763
-5,319
-15% -$22.8K ﹤0.01% 2218
2019
Q2 		$170K Buy
35,082
+2,690
+8% +$15.3K ﹤0.01% 1995
2019
Q1 		$265K Sell
32,392
-11
-0% -$75 ﹤0.01% 1708
2018
Q4 		$179K Buy
32,403
+11,644
+56% +$91.1K ﹤0.01% 1896
2018
Q3 		$183K Hold
20,759
– – ﹤0.01% 2061
2018
Q2 		$207K Buy
20,759
+6,578
+46% +$65.9K ﹤0.01% 1921
2018
Q1 		$135K Hold
14,181
– – ﹤0.01% 2132
2017
Q4 		$211K Sell
14,181
-15,760
-53% -$261K ﹤0.01% 1882
2017
Q3 		$589K Buy
29,941
+6,117
+26% +$94K ﹤0.01% 1572
2017
Q2 		$342K Sell
23,824
-7,516
-24% -$95.3K ﹤0.01% 1969
2017
Q1 		$288K Sell
31,340
-460
-1% -$4.49K ﹤0.01% 2033
2016
Q4 		$331K Hold
31,800
– – ﹤0.01% 2028
2016
Q3 		$288K Sell
31,800
-2,182
-6% -$18.5K ﹤0.01% 2091
2016
Q2 		$254K Hold
33,982
– – ﹤0.01% 2161
2016
Q1 		$306K Buy
33,982
+15,346
+82% +$124K ﹤0.01% 1886
2015
Q4 		$241K Buy
18,636
+16,684
+855% +$170K ﹤0.01% 2111
2015
Q3 		$19K Sell
1,952
-16,938
-90% -$155K ﹤0.01% 2657
2015
Q2 		$194K Buy
+18,890
New +$161K ﹤0.01% 2421
2014
Q3 		– Sell
-9,285
Closed -$258K – 2661
2014
Q2 		$258K Buy
+9,285
New +$224K ﹤0.01% 2324

Other funds holding AKBA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s AKBA Position: Q2 2022 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Akebia Therapeutics (AKBA) in Q2 2022, closing a stake of 11,718 shares — an estimated $8.41K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in AKBA in Q2 2014 and held it in 29 quarters. The position peaked at $589K in Q3 2017. 96 funds tracked by Wall St. Rank hold AKBA as of Q2 2022.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Akebia Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 11,718 Akebia Therapeutics shares in Q2 2022, an estimated $8.41K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Akebia Therapeutics in Q2 2014 and held it in 29 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Akebia Therapeutics position peaked at $589K in Q3 2017.
  • 96 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2022.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2022, filed 11 Aug 2022.